Research programme: diabetic retinopathy/neuropathy therapy - Scotia Holdings

Drug Profile

Research programme: diabetic retinopathy/neuropathy therapy - Scotia Holdings

Latest Information Update: 22 Jan 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QuantaNova Canada [CEASED]; Scotia Holdings [CEASED]
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies; Diabetic retinopathy

Most Recent Events

  • 22 Jan 2002 Discontinued-Preclinical for Diabetic neuropathies in Canada (Unknown route)
  • 22 Jan 2002 Discontinued-Preclinical for Diabetic retinopathy in United Kingdom (Unknown route)
  • 27 Jun 2000 QuantaNova Canada, the genomics-based discovery unit of Scotia, is investigating a therapeutic target for diabetic neuropathies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top